Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistantlocalization-related epilepsy: a systematic review
Autore:
Marson, AG; Hutton, JL; Leach, JP; Castillo, S; Schmidt, D; White, S; Chaisewikul, R; Privitera, M; Chadwick, DW;
Indirizzi:
Univ Liverpool, Clin Sci Ctr Res & Educ, Dept Neurol Sci, Liverpool L9 7LJ, Merseyside, England Univ Liverpool Liverpool Merseyside England L9 7LJ J, Merseyside, England
Titolo Testata:
EPILEPSY RESEARCH
fascicolo: 3, volume: 46, anno: 2001,
pagine: 259 - 270
SICI:
0920-1211(200109)46:3<259:LORAZF>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
REFRACTORY PARTIAL EPILEPSY; DOUBLE-BLIND; PARTIAL SEIZURES; TRIAL; TOLERABILITY; MULTICENTER; EFFICACY; THERAPY;
Keywords:
epilepsy; levetiracetam; oxcarbazepine;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Marson, AG Univ Liverpool, Clin Sci Ctr Res & Educ, Dept Neurol Sci, LowerLane, Liverpool L9 7LJ, Merseyside, England Univ Liverpool Lower Lane Liverpool Merseyside England L9 7LJ d
Citazione:
A.G. Marson et al., "Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistantlocalization-related epilepsy: a systematic review", EPILEPSY R, 46(3), 2001, pp. 259-270

Abstract

Objective: To undertake a systematic review and meta-analysis of placebo controlled add-on trials of levetiracetam, oxcarbazepine, remacemide and zonisamide for patients with drug resistant localization related epilepsy. Methods: We searched Medline, The Cochrane Library and contacted the relevant pharmaceutical companies. Outcomes were 50% or greater reduction in seizurefrequency and treatment withdrawal for any reason. Data were synthesised in a meta-analysis. The effect of dose was explored in regression models forlevetiracetam and remacemide. Results: We found four trials (1023 patients) of levetiracetam. two (961) of oxcarbazepine, two (388) of remacemide andthree (499) of zonisamide. Ignoring dose, the relative risks (95% CI) for a 50% response were 3.78 (2.62-5.44), 2.51 (1.88-3.33), 1.59 (0.91-2.97) and 2.46 (1.61-3.79), respectively. There was evidence for increasing effect with increasing dose for levetiracetam, oxcarbazepine and remacemide. The relative risks for treatment withdrawal were 1.21 (0.88-1.66), 1.72 (1.35-2.18), 1.90 (1.00-3.60) and 1.64 (1.02-2.62), respectively. Conclusions: These data suggest a useful effect for levetiracetam, oxcarbazepine and zonisamide. Levetiracetam has the more favourable 'responder-withdrawal ratio' followed by zonisamide and oxcarbazepine. (C) 2001 Published by Elsevier Science B.V.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 13:33:02